Acutaas Chemicals Limited reported robust financial results for the year ended March 31, 2026, achieving record annual revenue of INR 1,339.4 crore and a profit after tax (PAT) of INR 356.4 crore. Driven by strong performance in the CDMO business and Advanced Pharmaceutical Intermediates, the company maintains a positive outlook for FY27, guiding for 25% revenue growth as it scales its strategic investments in battery chemicals and semiconductor materials.
Record-Breaking Financial Performance
For the fiscal year 2026, Acutaas Chemicals delivered a strong performance, with revenue growing 33% year-on-year to reach INR 1,339.4 crore. The company’s focus on high-value products and operational efficiency resulted in its highest ever PAT of INR 356.4 crore, more than doubling compared to the previous year. Quarterly performance for Q4 FY26 was equally impressive, with revenue of INR 432.8 crore, reflecting a 40.3% year-on-year increase.
Strategic Business Vertical Updates
The company continues its transition into a diversified, multi-vertical entity. The Advanced Pharmaceutical Intermediates segment remains a primary growth engine, bolstered significantly by the CDMO business. Management highlighted a strong pipeline of validated products, with four new products expected to contribute between INR 50 crore and INR 100 crore each at peak capacity.
In the Specialty Chemicals and Semiconductor verticals, the company is seeing meaningful traction. The BFC (Baba Fine Chemicals) business has shown a strong recovery, and the new South Korean joint venture, Indichem, has initiated R&D operations and sample distribution, positioning it to scale alongside the semiconductor industry’s recovery.
Investment in Future Growth
Acutaas is prioritizing long-term growth through substantial infrastructure and innovation investments. Key highlights include:
- Battery Chemicals: The first phase of electrolyte additive capacity is complete, with the second phase expected to finish by Q1 FY27. The company has a 2,000 metric ton capacity for VC and FEC, fully backed by customer contracts for the next three years.
- R&D Expansion: A new, versatile R&D center is under development to facilitate cross-disciplinary innovation across the semiconductor, battery, and pharmaceutical sectors.
- Indichem JV: Construction of the plant in South Korea is on track for completion in the second half of calendar year 2026.
Future Outlook
Management is confident in maintaining its historical growth trajectory, guiding for 25% revenue growth in FY27. While acknowledging global supply chain challenges, the company expects to maintain steady EBITDA margins through a favorable product mix and operational leverage. The business remains focused on scaling its three key growth engines—pharmaceuticals, battery chemicals, and semiconductors—to ensure long-term value creation.
Source: BSE
